Epigenetic therapy in breast cancer

被引：33
作者：
Lustberg M.B. [1 ]
Ramaswamy B. [1 ]
机构：
[1] Division of Hematology and Oncology, Ohio State University Medical Center, Arthur G. James Cancer Hospital, Columbus, OH
来源：
Current Breast Cancer Reports | 2011年 / 3卷 / 1期
关键词：
Breast cancer; Demethylating agents; Epigenetic targets; Histone deacetylase inhibitors;
D O I：
10.1007/s12609-010-0034-0
中图分类号：
学科分类号：
摘要：
Breast carcinogenesis is a multistep process involving both genetic and epigenetic changes. Epigenetics is defined as reversible changes in gene expression, not accompanied by alteration in gene sequence. DNA methylation, histone modification, and nucleosome remodeling are the major epigenetic changes that are dysregulated in breast cancer. Several genes involved in proliferation, anti-apoptosis, invasion, and metastasis have been shown to undergo epigenetic changes in breast cancer. Because epigenetic changes are potentially reversible processes, much effort has been directed toward understanding this mechanism with the goal of finding effective therapies that target these changes. Both demethylating agents and the histone deacetylase inhibitors (HDACi) are under investigation as single agents or in combination with other systemic therapies in the treatment of breast cancer. In this review, we discuss the role of epigenetic regulation in breast cancer, in particular focusing on the clinical trials using therapies that modulate epigenetic mechanisms. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码：34 / 43
页数：9
相关论文
共 55 条
  • [1] Bird A., Perceptions of epigenetics, Nature, 447, 7143, pp. 396-398, (2007)
  • [2] Maass N., Biallek M., Rosel F., Schem C., Ohike N., Zhang M., Jonat W., Nagasaki K., Hypermethylation and histone deacetylation lead to silencing of the maspin gene in human breast cancer, Biochem Biophys Res Commun, 297, 1, pp. 125-128, (2002)
  • [3] Stearns V., Zhou Q., Davidson N.E., Epigenetic regulation as a new target for breast cancer therapy, Cancer Investigation, 25, 8, pp. 659-665, (2007)
  • [4] Yan P.S., Perry M.R., Laux D.E., Asare A.L., Caldwell C.W., Huang T.H.-M., CpG island arrays: An application toward deciphering epigenetic signatures of breast cancer, Clinical Cancer Research, 6, 4, pp. 1432-1438, (2000)
  • [5] Portela A., Esteller M., Epigenetic modifications and human disease, Nat Biotechnol, 28, 10, pp. 1057-1068
  • [6] Esteller M., Cancer epigenomics: DNA methylomes and histone-modification maps, Nature Reviews Genetics, 8, 4, pp. 286-298, (2007)
  • [7] Giacinti L., Claudio P.P., Lopez M., Giordano A., Epigenetic information and estrogen receptor alpha expression in breast cancer, Oncologist, 11, 1, pp. 1-8, (2006)
  • [8] Lopez-Serra L., Ballestar E., Ropero S., Setien F., Billard L.M., Fraga M.F., Lopez-Nieva P., Alaminos M., Guerrero D., Dante R., Et al., Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins, Oncogene, (2008)
  • [9] Esteller M., Molecular origins of cancer: Epigenetics in cancer, New England Journal of Medicine, 358, 11, (2008)
  • [10] Elsheikh S.E., Green A.R., Rakha E.A., Powe D.G., Ahmed R.A., Collins H.M., Soria D., Garibaldi J.M., Paish C.E., Ammar A.A., Et al., Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome, Cancer Res, 69, 9, pp. 3802-3809, (2009)
123456